Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $8.14 Average Price Target from Brokerages

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have been given an average recommendation of “Moderate Buy” by the ten research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $8.1429.

Several analysts recently commented on SANA shares. Citigroup reaffirmed an “outperform” rating on shares of Sana Biotechnology in a research note on Thursday, October 30th. Citizens Jmp lifted their price objective on Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a report on Thursday, October 30th. Bank of America upped their target price on shares of Sana Biotechnology from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Wall Street Zen upgraded shares of Sana Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Finally, Wedbush boosted their price target on shares of Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a research report on Friday, November 7th.

Sana Biotechnology Stock Performance

Shares of SANA opened at $4.07 on Monday. The company has a 50-day simple moving average of $4.56 and a 200-day simple moving average of $4.15. Sana Biotechnology has a 52 week low of $1.26 and a 52 week high of $6.55. The firm has a market capitalization of $1.08 billion, a P/E ratio of -4.20 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03. As a group, equities analysts forecast that Sana Biotechnology will post -1.16 earnings per share for the current year.

Institutional Trading of Sana Biotechnology

Hedge funds and other institutional investors have recently modified their holdings of the stock. Baillie Gifford & Co. raised its holdings in Sana Biotechnology by 13.6% during the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock worth $40,600,000 after purchasing an additional 1,371,775 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Sana Biotechnology by 19.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after buying an additional 1,517,474 shares during the period. Marex Group plc bought a new stake in shares of Sana Biotechnology during the second quarter worth approximately $10,423,000. JPMorgan Chase & Co. lifted its holdings in Sana Biotechnology by 180.8% in the third quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after buying an additional 1,375,029 shares during the period. Finally, Integral Health Asset Management LLC boosted its stake in Sana Biotechnology by 33.3% in the third quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock valued at $7,100,000 after acquiring an additional 500,000 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.